Our proprietary biological adjuvant technology platform involves combining particulate antigen formulations with membrane-linked cytokine and immunostimulatory protein adjuvants. Our biological adjuvants are linked to the antigen source to provide an enhanced immune response and stimulate specific immune pathways to achieve the desired immune response.
Membrex™ is an autologous immunotherapy platform that combines neoantigens and tumor-associated antigens from the patient’s tumor with our proprietary biological adjuvants. As our lead product platform, Membrex™ has remarkable potential to stimulate an immune response to immune checkpoint inhibitor (ICI) therapy-resistant and synergize with ICI therapy in preclinical cancer models. First-in-human Phase 1 clinical trials for advanced triple negative breast cancer and head and neck are expected to recruit patients in early 2024.
Our VaxRex™ vaccine platform consists of antigen-expressing virus-like particles (VLPs) with our membrane-anchored biological adjuvants. These VLP-based vaccine products for infectious disease prevention are designed to elicit potent humoral and cellular immunity and provide superior protection from viral infection, especially for the elderly and immune-compromised individuals.
Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing safety and effectiveness.
Metaclipse Therapeutics is developing a novel personalized vaccine immunotherapy platform, Membrex™, as a monotherapy and as part of combination therapy for the treatment of multiple advanced cancers including triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and HER2-positive breast cancer. First-in-human Phase 1 clinical trials for Membrex™ immunotherapy for triple negative breast cancer (TNBC) and head and neck squamous cell carcinoma (HNSCC) are expected to begin patient enrollment in early 2024.
Immune escape is one of major contributing factors for cancer progression. Further, cancer is highly heterogeneous and varies patient to patient. Membrex™, our cancer immunotherapy tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue modified using proven immunostimulatory proteins. After intradermal injection, Membrex™ delivers both immunostimulatory proteins and an array of patient-specific tumor-antigens simultaneously to the immune system resulting in suppression of cancer.
• Production does not require establishment of immortalized tumor cell lines, T cell cultures, or the use of viral vectors
• Includes all possible tumor antigens, addressing tumor heterogeneity
• Rapid, cost-effective manufacture and administration of the therapy to the patient within 3 weeks
• Particulate in nature, so optimal for uptake and processing by immune cells
• Physical linkage of biological adjuvants to tumor antigen source enhances immune response with a favorable safety profile
• Works in combination with immune checkpoint inhibitors (ICI) and enhances response rates for ICI-resistant cancers
We are developing a vaccine platform, VaxRex™, for infectious disease prevention consisting of ‘virus-like particles’ (VLP) modified using our proven biological adjuvants. After administration, VaxRex™ delivers both biological adjuvants and virus-specific antigens simultaneously in a particulate form to the immune system. VaxRex™ induced a robust virus-specific immune response in both young and aged animals. Metaclipse anticipates VaxRex™ will reduce infection rate and disease severity, especially for the elderly and immunocompromised individuals.
• Broad applicability, including vaccines for enveloped viruses such as influenza, SARS-CoV-2, and HIV
• Rapid manufacture of the vaccine with the ability to achieve much higher surface concentrations of membrane-anchored biological adjuvants in comparison to gene transfer
• Easily degrade in the system, suggesting they do not accumulate in the body upon repeated vaccinations, avoiding chronic side effects
• Physical linkage of membrane-bound adjuvants with antigens yields potent immune response and favorable safety profile
August 2023 − Metaclipse Therapeutics receives FDA clearance of its 2nd IND application for Membrex™ in head and neck cancer. Metaclipse received clearance from the U.S. Food and Drug Administration (FDA) for its 2nd Investigational New Drug (IND) application to initiate a Phase 1 clinical study of its personalized immunotherapy platform, Membrex™, in combination with an approved immune checkpoint inhibitor (ICI) for the treatment of recurrent and advanced metastatic head and neck squamous cell carcinoma (HNSCC) on August 23, 2023.
July 2023- Metaclipse Therapeutics signs a MOU with Syntekabio. Metaclipse signed a MOU with Syntekabio, an Artificial Intelligence (AI) based drug development company, for joint research on development of a personalized immunotherapy for cancer. With this MOU, Syntekabio plans to support Metaclipse in conducting research on neoantigen identification for its Membrex™ personalized cancer vaccine platform.
April 2023- Metaclipse Therapeutics received FDA clearance of its IND application for a first-in-human Phase 1 clinical trial of Membrex™ in triple negative breast cancer (TNBC). Metaclipse obtained clearance of its investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of its personalized immunotherapy platform, Membrex™, in combination with an approved immune checkpoint inhibitor for the treatment of early stage and metastatic triple negative breast cancer (TNBC) on April 5, 2023.
Membrex™ and VaxRex™ are investigational therapies and have not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of these therapies have not been determined.